Last reviewed · How we verify
NCT04185350
Clinical Evaluation of 68Ga-NOTA-MAL-Cys39-exendin-4 Positron Emission Tomography in the Detection of Insulinoma
EARLY_PHASE1 trial testing 68Ga-NOTA-MAL-Cys39-exendin-4 in Insulinoma in 60 participants. Status unknown.
5 April 2020
Quick facts
| Lead sponsor | Nanjing First Hospital, Nanjing Medical University |
|---|---|
| Phase | EARLY_PHASE1 |
| Status | Status unknown |
| Study type | INTERVENTIONAL |
| Allocation | na |
| Design | single group |
| Masking | none |
| Primary purpose | diagnostic |
| Enrollment | 60 |
| Start date | 5 May 2019 |
| Primary completion | 5 April 2020 |
| Estimated completion | 5 May 2020 |
| Sites | 1 location across China |
Drugs / interventions tested
- 68Ga-NOTA-MAL-Cys39-exendin-4 — full drug profile →
Conditions studied
- Insulinoma — all drugs for Insulinoma →
Sponsor
Nanjing First Hospital, Nanjing Medical University
Who can join
Adults 18 to 75, any sex, with Insulinoma. Patients with the condition only — healthy volunteers not accepted.
Sponsor's own description
Glucagon-like peptide-1 receptor (GLP-1R) is a kind of G protein coupled receptor which regulate the insulin secretion and serves as potential target in the diagnosis of functional pancreas neuroendocrine tumor. The aim of this study was the clinical evaluation of a potential GLP-1R targeted tracer 68Ga-NOTA-MAL-Cys39-exendin-4 for the detection of insulinoma.
Publications & conference data
1 peer-reviewed publication reference this trial (live from Europe PMC):
-
Evolving landscape of clinical trials in gastroenteropancreatic neuroendocrine neoplasms in the past two decades.
Yang K, Li J, Cheng Y, Bai C. · · 2023 · cited 3× · PMID 36724047 · DOI 10.1530/ec-22-0441
Verify or expand the search:
- PubMed search for NCT04185350
- Europe PMC full search
- ASCO Meeting Library
- ESMO Meeting Library
- bioRxiv preprints
- medRxiv preprints
- Google Scholar
Related trials
Other recruiting trials for Insulinoma
Currently open trials in the same condition.
- NCT06725693 — Glucagon-like Peptide-1 Receptor PET/CT in GLP-1R Related Disease · recruiting
- NCT03583528 — DOTATOC PET/CT for Imaging NET Patients · active not recruiting
- NCT00001276 — Diagnosing and Treating Low Blood Sugar Levels · recruiting
Other Nanjing First Hospital, Nanjing Medical University trials
Trials by the same sponsor.
- NCT07349979 — PCI With Guideline-Directed Medical Therapy for HFpEF Patients With Ischemic Cardiomyopathy · NA · not yet recruiting
- NCT07505056 — Jianpi Lishi Jiedu Granules for Prevention of Postoperative Recurrence in Colorectal Advanced Adenomas · Phase 3 · not yet recruiting
- NCT07397234 — Thyroid Cartilage Plane VS Superior Laryngeal Nerve Space Block in Awake Tracheal Intubation · NA · not yet recruiting
- NCT07455448 — Antibiotic Resistance of Helicobacter Pylori in Nanjing: A Cross-Sectional Study · completed
- NCT07385885 — Ultrasound-guided Non-invasive Simulation in Anesthesia Residency Training · NA · not yet recruiting
Verify against primary sources
- ClinicalTrials.gov — authoritative US registry record
- WHO ICTRP — international registry index
- EU Clinical Trials Register
- Sponsor press releases (Google)
- Trial protocol + status: ClinicalTrials.gov NCT04185350 (US National Library of Medicine, public domain)
- Publications: Europe PMC API search by NCT ID, retrieved 10 June 2026
- Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
- Sponsor: as reported to ClinicalTrials.gov by Nanjing First Hospital, Nanjing Medical University
- Last refreshed: 4 December 2019
Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT04185350.
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing